# Inhibitex

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inhibitex

- Industry: Pharmaceuticals
- Headquarters: Alpharetta, US
- Total disclosed funding: $60M
- Latest round: Series D (Apr 18, 2002)
- Investors on record: 10

## About

Founded in 1994 and based in Georgia, US,  Inhibitex, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes antibody-based products for the prevention and treatment of fungal and bacterial infections in the hospital setting.

## Funding rounds

- Series D, Apr 18, 2002, $3.6M — Burrill & Company, William Blair Capital Partners
- Series D, Feb 11, 2002, $41M — Essex Woodlands, New Enterprise Associates, Pacific Horizon Ventures, William Blair Capital Partners, CDPQ, Alliance Technology Ventures
- Series C, Jun 1, 2000, $15M — Pacific Horizon Ventures, William Blair Capital Partners, AM Fund, Cordova Ventures, Alliance Technology Ventures, Oakwood Medical Investors

## Investors

- Pacific Horizon Ventures (https://capitalatlas.ai/funds/pacific-horizon-ventures) — Series C, Series D
- William Blair Capital Partners (https://capitalatlas.ai/funds/william-blair-capital-partners) — Series C, Series D
- AM Fund (https://capitalatlas.ai/funds/am-fund) — Series C
- Cordova Ventures (https://capitalatlas.ai/funds/cordova-ventures) — Series C
- Alliance Technology Ventures (https://capitalatlas.ai/funds/alliance-technology-ventures) — Series C, Series D
- Oakwood Medical Investors (https://capitalatlas.ai/funds/oakwood-medical-investors) — Series C
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series D
- CDPQ — Series D
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series D